Outcome of the Board Meeting held today i.e, Wednesday, 13th August, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemo Organic's board approved the unaudited Q1 FY26 (quarter ended June 30, 2025) standalone results. Revenue from operations collapsed to just ₹0.19 lakh versus ₹241.43 lakh in the same quarter last year — a near-total wipeout. Total income fell to ₹9.14 lakh from ₹248.42 lakh, and the company swung to a net loss of ₹8.57 lakh compared to a profit of ₹37.34 lakh in Q1 FY25. EPS turned negative at ₹(0.25) versus ₹1.08. The statutory auditor issued a qualified limited review report, flagging missing balance confirmations for trade payables and receivables. The board also finalised the 33rd AGM for September 29, 2025 (via video conferencing) and noted a ₹11,800 penalty already paid to BSE for non-compliance with Regulation 29(2)/29(3) (prior intimation of board meeting).
This is a clearly negative filing for shareholders — the near-total revenue collapse and return to losses suggest the core business has stalled, and the auditor's qualification on trade receivables/payables adds governance risk. The penalty itself is minor, but the operational picture is worrying; expect negative sentiment and pressure on the stock.